Gladius Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Gladius Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-96	Closed	-$32.1K	–	95
2024 Q3	$32.1K	Buy	+96	New	+$30.5K	﹤0.01%	202
2024 Q1	–	Sell	-121	Closed	-$39.1K	–	326
2023 Q4	$39.1K	Buy	121 +48	+66%	+$15K	0.01%	213
2023 Q3	$26.2K	Buy	73 +18	+33%	+$6.95K	﹤0.01%	324
2023 Q2	$20.8K	Buy	+55	New	+$22.4K	﹤0.01%	302
2022 Q4	–	Sell	-75	Closed	-$32K	–	362
2022 Q3	$32K	Buy	+75	New	+$37.4K	﹤0.01%	293
2022 Q2	–	Sell	-190	Closed	-$108K	–	360
2022 Q1	$108K	Buy	+190	New	+$115K	0.01%	213

Other funds holding BIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Gladius Capital Management's BIO Position: Q4 2024 in Review

Gladius Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2024, closing a stake of 96 shares — an estimated $32.1K sold.

Gladius Capital Management first reported a position in BIO in Q1 2022 and held it in 6 quarters. The position peaked at $108K in Q1 2022. 457 funds tracked by Wall St. Rank hold BIO as of Q4 2024.

Gladius Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2024 after selling out during the quarter.
Gladius Capital Management sold 96 Bio-Rad Laboratories Class A shares in Q4 2024, an estimated $32.1K.
Gladius Capital Management first reported a position in Bio-Rad Laboratories Class A in Q1 2022 and held it in 6 quarters.
Gladius Capital Management's Bio-Rad Laboratories Class A position peaked at $108K in Q1 2022.
457 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2024.

Based on Gladius Capital Management's 13F filing for Q4 2024, filed 31 Jan 2025.